Jon Skinner Hired to Manage Pulse Biosciences Finances

Pulse Biosciences Inc. has welcomed a new member to its executive team, appointing Jon Skinner as chief financial officer (CFO).

“I am excited to announce Jon as our next CFO, further building upon our momentum at Pulse Biosciences. His experience as a financial leader at both growth stage and scaled public diversified medtech companies will be extremely valuable in our efforts to advance our nanosecond PFA technology platform,” Pulse Biosciences Co-Chairman/CEO Paul LaViolette said. “Jon will be a fantastic addition to our leadership team and we look forward to benefitting from his strategic and financial insights as we scale commercialization and our operations.”

Skinner is an accomplished financial leader with significant healthcare experience. He most recently served as vice president, FP&A and Investor Relations at Copeland, a private equity backed industrial company. Before that, he was vice president, Finance and Corporate Development at Imperative Care, a venture backed medical technology company. There, he spearheaded M&A, strategy, partnerships, and sales operations along with providing financial and strategic support for all development stage business units. While at Imperative Care, he also served as the interim CFO of Kandu Health during its spin-out and fundraising process.

Prior to Imperative Care, Skinner was vice president, Finance – Interventional Urology at Teleflex. While there, he led accounting, FP&A, customer service, and sales operations for the Interventional Urology Business Unit, following his role as senior director, Corporate Development, where he helped close 25 M&A transactions. Before Teleflex, Skinner spent time at Axalta Coating Systems working on its carve-out and IPO and at Duff & Phelps (now Kroll) in the Valuation Advisory Group.

Skinner earned a bachelor of science degree and an MBA from The Ohio State University.

“I am thrilled to be joining Pulse Biosciences at this exciting point in the company’s history. I believe nanosecond PFA will be a disruptive catalyst to advance the treatment of several disease states representing very large markets,” Skinner stated. “I look forward to working alongside this management team and leveraging my experience to drive disciplined growth and operational excellence.”

Pulse Biosciences is a bioelectric medicine company whose proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The company is actively pursuing the development of its CellFX nsPFA technology for use in treating atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers. Pulse Biosciences is now headquartered in Miami, Fla., and maintains an office in Hayward, Calif.